Effect of Tanreqing on procalcitonin and T lymphocyte subsets in patients with acute exacerbation of chronic obstructive pulmonary disease
FAN Lizhen1 XIONG Jiangqin1 YU Jia2
1. Department of Internal Medicine, Jiangxi Chest Hospital, Jiangxi Province, Nanchang 330006, China;
2. Department of Pharmacy, the Third Affiliated Hospital of Nanchang University, Jiangxi Province, Nanchang 330008, China
Abstract：Objective To investigate the effect of Tanreqing on procalcitonin (PCT) and T lymphocyte subsets in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods A total of 100 patients with acute exacerbation of COPD who were treated in the Department of Internal Medicine, Jiangxi Chest Hospital from January 2017 to December 2019 were selected as the research subjects, they were divided into an observation group and a control group by random number table method, 50 cases in each group. The patients in the control group received conventional treatments such as oxygen inhalation, bronchodilators and anti-infection, patients in the observation group were treated with Tanreqing Injection on the basis of the control group. Both groups continued treatment for one week.The immune function, peripheral blood PCT and C-reactive protein (CRP) levels were compared between the two groups before and after treatment. Results There were no statistically significances in the levels of PCT, CRP, CD4+/CD8+, CD4+and CD8+ in the peripheral blood of the patients in the two groups before treatment (P＞0.05). The levels of CD4+/CD8+ and CD4+ in the peripheral blood of the patients in the two groups after treatment were higher than those before, the levels of CD4+/CD8+ and CD4+ in the peripheral blood of the patients in the observation group were higher than those of the control group, and the differences were statistically significant (P＜0.05). The levels of CD8+, PCT and CRP levels in the peripheral blood of the patients in the two groups after treatment were lower than those before treatment, the levels of CD8+, PCT and CRP levels in the peripheral blood of the patients in the observation group were lower than those of the control group, and the differences were statistically significant (P＜0.05). Conclusion Tanreqing can improve the immune function of patients with acute exacerbation of COPD, reduce the inflammatory response, and relieve patients′ symptoms.
范励侦;熊江琴;虞佳. 痰热清对慢性阻塞性肺疾病急性加重期患者降钙素原和T淋巴细胞亚群的影响[J]. 中国当代医药, 2022, 29(2): 48-51.
FAN Lizhen;XIONG Jiangqin; YU Jia. Effect of Tanreqing on procalcitonin and T lymphocyte subsets in patients with acute exacerbation of chronic obstructive pulmonary disease. 中国当代医药, 2022, 29(2): 48-51.
京公网安备 11010502046607号